In previously reported studies, we observed significantly high genotoxicity biomarkers in regularly transfused thalassaemic patients, thus, in this study, we better investigated the genotoxic effect of iron overload and of thalassaemia complications, including their drug treatments. The assessment was performed in 64 regularly transfused thalassaemic patients using cytokinesis-block micronucleus and comet assays. All patients were splenectomised and undergoing iron chelation therapy. To reduce hypoxia-induced oxidative damage, the patients with haemoglobin levels <9.5 g/dL were excluded. Serum concentrations of ferritin, iron, transferrin and the percentage of transferrin saturation, as well as cardiac and hepatic T2* magnetic resonance imaging, were considered to evaluate serum and organ siderosis.
Introduction
Genome instability is one of the most important aspects of cancer, and alterations found in tumours include subtle changes in DNA sequence as well as cytogenetically visible changes such as chromosome losses or gains, translocations and deletions (1) . These changes are early biomarkers of genotoxicity and their detection has a pivotal role in cancer prevention.
The cytokinesis-block micronucleus (CBMN) assay allows evaluation of the chromosomal damage or nuclear instability status by assessing the frequency of micronuclei (MNi). These originate from chromosome breakage and/or aneuploidy (2) and correlate with the incidence of cancer in humans (3, 4) .
Alkaline single-cell gel electrophoresis, commonly called the 'comet assay', is a sensitive and rapid method for detecting DNA strand breaks at the individual cell level (5, 6) . A number of reports have suggested that the comet and CBMN assays have potential applications in biomonitoring studies that assess genotoxicity due to endogenous as well as exogenous factors, drugs included (7) . In particular, due to its greater ability to predict cancer, the CBMN assay is considered an early biomarker of carcinogenesis (3) .
The lymphocytes are preferred cell model for these indicators, as they are an 'ideal biological dosimeter'-they circulate throughout the body and record genotoxic insults received in various parts of the organism. Lymphocytes 'store' the result of these contacts and can express the 'knowledge' acquired after in vitro activation. If the accumulated damage is not remedied in the quiescent phase of the cell cycle (G0), it can be detected when the cells undergo mitotic division in vitro. Thus, an increased lymphocytic MNi frequency can be the result of cumulative effects, due to recent or previous exposures (8) .
Malignancies were considered rare in β-thalassaemia, but recently the number of thalassaemic patients with cancer has increased. In addition to hepatocellular carcinoma (HCC), frequently diagnosed in haemochromatosis but also in thalassaemias, other types of cancer including leukaemias are observed (9) (10) (11) (12) (13) . Our previous report, underlining the significant increases in MNi frequency highlighted this potential risk in thalassaemia (14) .
The relationship between cancer and iron overload is well known. Redox-active iron (i.e. non-transferrin-bound iron) is the main source of radicals and organic reactive species that are strongly related to oxidative damage and carcinogenesis (15, 16 ).
β-Thalassaemia major patients present an inherited severe chronic haemolytic anaemia requiring regular red blood cell (RBC) transfusion therapy that leads to iron overload and its related complications. Since the 1970s, the use of lifelong iron chelation therapy has increased the life expectancy of transfused dependent thalassaemic patients (17) , limiting iron overload complications (18) .
Although the leading cause of death is cardiac failure (i.e. dilated cardiomyopathy), liver diseases (liver fibrosis and cirrhosis), gonadal insufficiency and other endocrinal dysfunctions are well recognised in transfusion-dependent thalassaemic patients. These complications, reflecting organ damage, are related mainly to secondary haemosiderosis. Hypogonadism, the most common endocrinopathy in thalassaemic patients (19, 20) , may result from iron deposits in the hypothalamic-pituitary cells or in the gonads. Other common endocrine complications in thalassaemic patients are short stature, thyroid and parathyroid dysfunctions and diabetes. In addition, osteopoenia and osteoporosis represent the most common bone metabolic disorders and the prominent causes of morbidity in thalassaemia.
Iron overload-induced liver fibrosis can be exacerbated by intercurrent transfusion-dependent viral infection (21) . Chronic liver hepatitis can evolve to cirrhosis and HCC that is very frequent in thalassaemia (22) .
Although myocardial iron overload is traditionally thought to be the main cause of thalassaemic cardiomyopathy (23) , the appropriateness of the transfusion regimen and the possibility of a chronic anaemic state, increasing cardiac output, must also be considered as causes of morphologic alterations (24) .
We have previously observed that anaemia-induced hypoxia is an additional source of oxidative damage, while significantly high genotoxicity, observed in regularly transfused patients, could be linked to thalassaemia complications and siderosis (14) .
Based on these findings, we aimed herein to investigate in a homogenous group of transfused thalassaemic patients the genotoxic/cytotoxic effect of iron overload and of thalassaemia complications, including their drug treatments. The assessment was performed, using CBMN (25) and comet assays (26) , in regularly transfused patients, all splenectomised and with haemoglobin (Hb) values ≥9.5 g/dL, in order to reduce hypoxia-induced DNA damage (27) .
Materials and Methods

Patients
Sixty-four transfusion-dependent β-thalassaemic patients (34 women and 30 men) were recruited a priori from the Messina University Hospital, Italy. The local hospital ethics committee approved the study, and all patients gave their informed consent.
All patients included in the study were splenectomised, because hypersplenism, by a marked haemocatheresis, causes the removal of more damaged lymphocytes and the underestimation of cellular and genotoxicity biomarkers (14) . Moreover, to reduce hypoxia-induced oxidative damage (27) , those with Hb levels <9.5 g/dL were also excluded. As expected from the therapeutic protocol of poly-transfused patients, all patients were undergoing iron chelation therapy that was not suspended before sampling. Twenty-two patients were treated with deferasirox, 14 with deferoxamine (DFO), 10 with deferiprone (DFP) and 18 with combined DFO + DFP.
Twenty healthy individuals matched with the patients for age and gender (12 women and 8 men) were used as a control group (C).
Blood samples were collected from each subject in the morning and, in patients, before packed RBC transfusion. The average interval between transfusions was 15-20 days. The number of total transfused RBCs (mL/kg/year) was calculated using the equation:
RBCs Annual blood intake 65 haematocrit 65 kg body weig
Iron intake was obtained by multiplying the result by 1.08 (28) . Serum concentrations of ferritin, iron, transferrin and the percentage of transferrin saturation (%TSAT), as well as cardiac and hepatic T2* magnetic resonance imaging (MRI T2*) were considered to evaluate serum and organ siderosis.
Comet and CBMN assays
The parameters of genotoxic damage were analysed in lymphocyte suspensions from heparinised blood using previously reported protocols (14) . The CBMN assay was performed in lymphocytes that had been previously stimulated with PHA (2%) and then treated with cytochalasin B (4.5 mg /mL) to block cytokinesis (26) . In the fixed and Giemsa-stained cells, MNi and micronucleated cells (MNed), were scored to measure chromosomal DNA damage, according to CBMN criteria (25) .
The comet assay was performed in duplicate according to the method proposed by Tice et al. (5) . DNA unwinding and lysis were performed for 20 min and 1 h, respectively, whereas electrophoresis was carried out for 30 min at 300 mA and 25 V (0.86 V/cm). Analyses were carried out using a DM IRB fluorescence microscope at 400× magnification (Leica Microsystem). Images of at least 100 randomly selected nuclei (ethidium bromide stained 2 mg/mL in water) were analysed by the CASP automated image analysis system (http://www.casp.sourceforge.net) (14) . In addition to percentage of DNA in tail (%TDNA), comet assay results were reported as DNA density, whose values were obtained computing the ratio between percentage head DNA and head diameter, both standardized endpoints of comet assay, supplied by CASP analysis. This unusual parameter, considered by us as marker of chromatin compactness, was used to evaluate abnormal comets without or with small tail and with a particularly large head (14) . The structures that were almost exclusively present in the patient spots were formed in the unwinding phase and were presumably due to the ability of the highly damaged DNA strands to spread radially at alkaline pH even in the absence of an electric field. Unlike classical parameters that analyse exclusively the tail of comet to evaluate DNA mobility (i.e. %TDNA, tail moment and Olive tail moment), the DNA density highlights a greater sensitivity, allowing to assess the early mobility of highly damaged DNA. It is useful to underline that, paradoxically, despite the presence of this damage, the radial spread causes an underestimation of the classical parameters of comet assay as it limits the formation of long tails with high percentage of DNA when the electrophoresis is performed.
Statistical analyses
Analyses were performed using the Statistica programme (version 10). Lilliefors and Shapiro-Wilk normality tests were used to assess data distribution patterns. Continuous variables were expressed either as mean ± standard deviation (SD) or as median and interquartile intervals.
The impact of the independent variables on the genotoxicity endpoints was evaluated using the non-parametric Mann-Whitney and Spearman tests. A P value <0.05 was considered statistically significant. Table 1 reports the haematological parameters of iron and genotoxicity endpoints in thalassaemic patients (T) and the control group (C). Iron intake per year and cardiac and hepatic MRI T2* are reported. There were no differences in the male/female ratio (X 2 = 0.20 P = 0.65) or age. The SD values and the interquartile intervals highlight the very high intra-T group variability for many of the parameters considered. This heterogeneity emphasised the broad spectrum of secondary clinical complications in thalassemic cohort, composed of 64 regularly transfused thalassaemic patients, all splenectomised and with Hb levels ≥9.5 g/dL. There was a high prevalence of endocrinopathies. In particular, 26 patients had hypothyroidism (40.6%) and were undergoing levothyroxine therapy, 36 (56.2%) presented hypogonadism and 26 (40.6%) were undergoing hormone replacement therapy (HRT). Seven (10.9%) had diabetes mellitus (DM), and 10 (15.6%) had short stature. Overall, 20 (31.2%) of the patients had at least one endocrine disease and 23 (35.9%) had two or more.
Results
Thirty-one patients (48.4%) had osteopenia, defined by the WHO as a T-score between −1 and −2.5, and 30 (46.9%) had overt osteoporosis, recording a T-score above 2.5. The thalassaemic group also included 23 (35.9%) patients with hepatic disease and 20 (31.2%) with active hepatitis C virus (HCV) infection. As diagnosed by hepatic and heart MRI T2* values, 20 (31.2%) patients had hepatic siderosis and 7 (10.9%) had myocardial siderosis (<6.3 ms and <20, respectively).
As expected, iron indices were higher in the T group than in the C group (P < 0.01). The values for genotoxic endpoints obtained by CBMN and comet assays (MNi, MNed and %TDNA) were significantly increased in patients compared with the controls. Conversely, DNA density, marker of chromatin compactness was lower in T than in C-subjects.
Within the T group patient cohort, there were no differences according to chelation treatments for iron parameters, iron intake, cardiac or hepatic MRI T2* or for the endpoints assessed (data not shown). Table 2 reports the results of Spearman test in the patient cohort, highlighting the relationships between iron overload indices and the assessed endpoints. The parameters of iron status showed unexpected relationships with genotoxic endpoints. Serum ferritin was associated with increased DNA density and was inversely related to MNi and MNed frequency, and iron intake via blood transfusions was inversely related to %TDNA. Conversely, serum iron and %TSAT were related to DNA damage as measured by increased %TDNA and decreased DNA density.
Besides these relationships with the genotoxicity endpoints, the iron indices were interrelated. More precisely, heart and hepatic MRI T2* were inversely related to serum ferritin (R = − 0.35, P = 0.02 and R = −0.51, P < .0.001, respectively). Ferritin was also inversely related to %TSAT (R = −0.29, P = 0.03), while no correlation was found between hepatic and heart MRI T2* and iron intake. Genotoxicity endpoints also were interrelated and, conversely to % TDNA, DNA density, marker of chromatin compactness, was significantly related with MNi (Figure 1) , enhancing the value of this parameter.
The genotoxic effects of disease complications with high prevalence in β-thalassaemia were assessed. These included hepatic disease, active HCV infection, hypothyroidism, hypogonadism DM, short stature and bone disease (osteopenia and osteoporosis), along with their respective drug therapies. The conditions significantly affecting genotoxicity biomarkers are reported in Table 3 , where patients are grouped according to the absence/presence of each complication or therapeutic treatment. As highlighted by the interquartile range, the variability was kept high in each subgroup. Considering the complexity of the disease, the absence of a secondary complication or therapeutic treatment did not necessarily exclude the other. Similarly, the simultaneous presence of more complications was not to excluded. Despite this, active HCV infection, drug therapy for osteoporosis and HRT therapy for hypogonadism elicited a significant genotoxic effect to Mann-Whitney test.
In particular, HCV-induced genotoxicity was emphasised by the frequency of MNi/MNed and by %TDNA values. As shown in Figure 2 , the DNA damage increased up to 2-fold (P < 0.01 for all centiles) in HCV-RNA-positive patients, in comparison with the negative ones.
While osteopenia/osteoporosis not directly affected genotoxicity endpoints, their therapeutic treatment by bisphosphonates caused significant genotoxic damage ( Table 3 ). The effect in thalassaemic patients with bone disease under bisphosphonate therapy compared with those without is highlighted in the box plot ( Figure 3A) .
No differences in the assayed endpoints were observed in relation to hypogonadism, while a genotoxic effect was observed in the patients undergoing HRT (40.6%). In comparison with untreated patients, their MNi frequency was significantly higher ( Figure 3B ) and the genotoxicity of the treatment was confirmed by DNA density measurements (Table 3) .
These conditions significantly affecting genotoxicity biomarkers were simultaneously present in some patients and, while only one was present in 39%, the coexistence of two and three conditions was present in 15% and 13%, respectively. As expected, the group of 45 subjects with complications and/or therapeutic treatments showed higher genotoxicity than the 20 patients without (DNA density: Z = 3.87, P < 0.001; MNi: Z = 3.11, P < 0.01 and MNed Z = 2.91, P < 0.01). Owing to the decreased sample size for each group, patient cohort stratification according to the presence of one, two or three genotoxic conditions reduced the statistical power. Despite this, a gradient in assayed endpoints was observed. In comparison with the patients without genotoxic conditions (median values 0.50, 13.8 and 13.2 for DNA density, MNi and MNed, respectively), the differences were significant for DNA density, whose median values were 0.37 (Z = 3.52; P < 0.001) and 0.33 (Z = 3.75; P < 0.001) in the presence of one and two conditions, respectively. Similar significant differences were observed in MNi/MNed frequency. When two conditions coexisted, the median values were 19.8 (Z = 2.8; P < 0.01) and 18.4 (Z = 2.7; P < 0.01), respectively. MNi/MNed frequency increased further when three determinants coexisted and median values were 46.0 (Z = 2.8; P<0.01) and 41.0 (Z = 2.9; P < 0.01).
In particular, the coexistence of HCV infection and HRT for hypogonadism seemed to enhance the genotoxicity considerably. In comparison with the patients in HRT treatment only, %TDNA median value was 26.39 vs. 7.96 (Z = 2.8; P < 0.01) and DNA density was 0.36 vs. 0.45 (Z = 2.16; P = 0.03). Similar differences were observed in MNed frequency comparing these patients to those with only HCV infection (median value 20.5 vs. 14.5, Z = 3.5, P < 0.01).
Discussion
Regular transfusion regimens and effective iron chelation therapy have significantly improved the life expectancy of thalassaemic subjects. However, in comparison with the general population, recent reports indicate their increased risk of malignancies, particularly haematologic malignancies (9, 10) , in addition to the well-known risk of HCC (22) .
The strong link between genotoxicity and carcinogenesis is proven, and both the comet assay and CBMN are used in human biomonitoring to measure DNA damage as biomarkers of exogenous and endogenous genotoxic insults and of cancer risk, respectively (3, 26) . 
The results are expressed respectively as r and P values. Only the parameters significantly related to the assayed endpoints are reported.
Our previous report on transfused and untransfused thalassaemic patients showed a significant genotoxicity, particularly in transfused patients, whereas oxidative damage was increased in untransfused patients (14) . In order to reduce the high inter-individual variability, in the present study, we selected a homogenous population of transfusion-dependent thalassaemic patients. To evaluate the genotoxic effects of iron overload and disease complications, the patients were all splenectomised and had Hb values ≥9.5 g/dL, in order to limit hypoxia-induced DNA damage (27) . However, this exclusion criteria were not sufficient to reduce the high variability in the patient group, due to the disease complexity. The multi-organ effects of secondary siderosis and the higher risk of blood-transmitted HCV infection of thalassemic patients would have made necessary to examine a larger number of subjects. Despite the lower statistical power of the results, i.e. the limitation of our study, we confirmed the significant genomic instability in transfused thalassaemic patients compared with health subjects. In addition, the results highlighted the combined effect of iron overload and, mainly, disease complications, including their respective pharmacological treatments.
The genotoxic effect of iron overload, almost completely due to blood transfusion performed in conjunction with lifelong iron chelation therapy, was underlined by some of the iron indices examined. In particular, the results of bivariate analysis revealed that the parameters seemingly more predictive of iron genotoxicity were serum iron concentration and %TSAT. These were significantly related to DNA damage as assessed by the comet assay.
The strong relationships between serum ferritin and iron stores in the liver and heart, as assessed by MRI, highlighted that ferritin is an excellent marker of siderosis. This was confirmed by Chuansumrit et al. (29) and Rostoker et al. (30) and underlines that the disturbing factor, due to the role of ferritin as an acute phase reactant (31) , is negligible in the presence of high ferritin levels caused by iron overload. Despite its predictive significance for siderosis, our data show that serum ferritin, in addition to iron intake, cardiac and hepatic MRI T2*, had unexpected relationships with genotoxicity endpoints. In agreement with our previous report (14) , these results highlight that in thalassaemic patients, other factors, and in particular, anaemia, have a greater impact than iron overload in genotoxicity (32) .
In order to maintain adequate Hb levels, the required annual blood intake is different for each patient. An appropriate transfusion regimen reduces the genotoxic effect of anaemia, as underlined by the inverse relationship between %TDNA and the amount of blood intake but could increase the indices of iron overload if not coupled with an effective iron chelation therapy.
Other factors affecting DNA integrity in our patients were disease complications and theirs drugs treatments. A reduction in the risk of HCV transfusion-associated infection has been recorded in younger generations of thalassaemic patients in developed countries, due to the screening for HCV in donated blood undertaken since the early 90s (21) . However, the carcinogenic potential of active HCV infection should not be underestimated in older patients. The significantly higher values of lymphocytic MNi/MNed frequency and of %TDNA, in our HCV-RNA-positive thalassaemic patients, confirmed the increased chromosomal instability reported by Machida et al. (33) HCV genotoxicity can be attributed to free radical overproduction, also caused by infectioninduced phlogosis (34) . Comparable results in HCV-infected patients were also observed by detecting 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG), the most frequent oxidative premutagenic DNA lesion (35, 36) . Considering the high risk of liver malignancies in iron overload conditions and the strong link between chronic HCV and HCC (37), our results in β-thalassaemia are considerably important. Liver fibrosis and its progression to cirrhosis and cancer are mainly due to siderosis, in comparison with HCV infection (38) . Despite this, the co-presence of both factors synergistically increases the HCC risk (22) and antedates its onset (39) , confirming the need for thalassaemic patients with active HCV infection to undergo close screening.
Accelerated haemopoiesis with marrow expansion, endocrinopathies, direct iron toxicity on osteoblasts and chelation-induced osteoblast impairment are responsible for a reduction in bone mineral density (40) . Osteopoenia and osteoporosis were widely found in our patients, some of whom were treated with bisphosphonates. Although it has been reported that alendronate does not increase sister chromatid exchange (41), using CBMN and comet assays, we have shown a significant genotoxic effect of the drug which is consistent with that described for postmenopausal women (42) .
A comparable genomic instability was induced by HRT for hypogonadism that significantly increased the MNi frequency in our patients. Although the very few previous studies that have considered the potential genotoxicity of hypogonadism treatment have given conflicting results (42-44), our results clearly highlighted this druginduced effect. This could be caused by diffuse lesions, attributable to oxidative DNA damage (14) . These results would suggest that oestrogens and/or their metabolites may directly or indirectly induce genetic instability and cell mutations by radical-induced damage.
Similarly to MNi, a parameter that proved to be extremely sensitive, was DNA density that we used to assess the chromatin compactness (14) . Its usefulness as genotoxicity biomarker seems confirmed by the inverse relationships with MNi, index of nuclear instability status.
Overall, the values of genotoxicity biomarkers reported in this study underline the fact that the increased risk of malignancies in transfused thalassaemic patients is multifactorial. Indeed, in addition to iron genotoxicity counteracted, though not completely, by chelation therapy, disease complications and their drug treatments play a key role. In particular, when disease complications and/or drug treatments coexist, the resulting genotoxic effects seem to be at least additive. On this basis, it is highly recommended to constantly monitor thalassaemic patients in order to prevent the onset of malignance or to diagnose it as quickly as possible.
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